This study assessed the impact of tenofovir-based pre-exposure prophylaxis (PrEP) on HIV disease progression in women who seroconverted. The authors found no significant effect on disease outcomes and demonstrated the feasibility and benefits of long-term follow-up of seroconverters using PrEP. As PrEP continues to be introduced in various settings, these data are important for policymakers and ministries of health to better understand the clinical outcomes of PrEP seroconverters.
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial
Written By
Riddler SA, Husnik M, Ramjee G, Premrajh A, Tutshana BO, Pather A, Siva S, Jeenarain N, Nair G, Selepe P, Kabwigu S, Palanee-Phillips T, Panchia R, Mhlanga F, Levy L, Livant E, Patterson K, Elharrar V, Balkus J
